scorecardresearch
Friday, March 29, 2024
TopicSerum Institute India

Topic: Serum Institute India

Respect govt decision to bar Covishield export, expect nod in March-April, says Serum CEO

Adar Poonawalla, CEO of Serum Institute of India, says the govt restrictions ‘will be eased out very soon once the most vulnerable population starts getting vaccinated’.

DCGI’s Covaxin ‘approval’ is political jumla. It reinforces idea of Modi’s Atmanirbhar Bharat

The Modi govt must not damage India’s competitive advantage in vaccines & pharmaceuticals through absurd benchmarks that will not be trusted by other countries.

Oxford vaccine to cost Rs 219-292 to govt, double for private buyers, says Adar Poonawalla

The Serum Institute of India CEO said Covishield will be sold to the govt and Global Alliance for Vaccines and Immunization countries first and on the private market later.

Serum expects govt to sign pricing deal for Covishield within days

Officials have 'indicated orally' that first 100mn vaccines will be purchased at Rs 200 & a deal should be inked 'in next one or two days', according to Serum CEO Adar Poonawalla.

Everything we know about Covishield, one of 2 Covid vaccines likely to get nod for use in India

Covishield is Serum Institute of India’s version of the Oxford-AstraZeneca vaccine that had been in the works for several months.

Health Minister Vardhan launches India’s first indigenous pneumococcal vaccine Pneumosil

Pneumosil, developed by SII in collaboration with partners like Bill and Melinda Gates Foundation, will be available at an affordable price, the health ministry said.

Serum Institute has produced 40-50 million doses of Covishield vaccine, says Adar Poonawalla

The Serum Institute CEO also said the vaccine rollout is expected to be slow in the initial phase due to some logistics issues and is expected to pick up once things get sorted.

Govt looks into new vaccine data after Pfizer, Bharat Biotech, SII seek emergency use approval

Govt had sought additional data on the vaccine candidates of companies seeking emergency use authorisation. So far, just one company has submitted this information.

UK says Oxford vaccine review ongoing, won’t be approved until safety, efficacy standards met

UK's Medicines and Healthcare products Regulatory Agency tells ThePrint vaccine review includes poring over pages of lab data. If cleared, it will likely boost chances of the vaccine's approval in India.

UK likely to approve Oxford Covid vaccine by year-end, may help boost its chances in India

The trials for the vaccine in India are being carried out by Serum Institute of India (SII) and the company has applied for its emergency authorisation use.

On Camera

Congress attacks chief economic advisor over statement on unemployment, asks BJP govt to ‘vacate seat’

While releasing 'India Employment Report 2024', V Anantha Nageswaran said govt can't solve 'all social, economic challenges'. Congress leader Kharge says CEA protecting 'dear leader'.

Amid plans to lift AFSPA, Army starts joint training with Jammu & Kashmir Police

In an interview with Gulistan News this week, Union Home Minister Amit Shah said the government would leave law and order to J&K Police and slowly withdraw troops.

For BJP, Kejriwal is an idea whose time has come to be destroyed

The ‘idea’ Kejriwal's politics grew around was a no-holds-barred fight against corruption. That is the reason Modi govt has now tarred him and his entire party with the same paint.